The Pentagon on Thursday, September 3, 2026, temporarily rescinded newly issued clinical guidance that mandated testosterone deficiency screening for male active-duty and reserve service members aged 30 and older. A Pentagon official stated the documents were removed to allow for unspecified "updates," though the official noted that an "Interim Guidance on Testosterone Deficiency Screenings" remains in effect.
The rescinded guidance, titled "Clinical Guidance for Health and Human Performance Optimization," was unveiled on Wednesday, September 2, and was intended to take effect immediately. It outlined mandatory testosterone blood tests for men over 30 and directed health professionals to screen younger men if requested or deemed medically necessary. The documents also included screening questionnaires for female service members regarding hormonal dysregulation and disrupted menstrual cycles.
Defense Secretary Pete Hegseth first announced the screening initiative in July 2026, describing it as a method to maintain the "decisive tactical advantage" of individual service members. Hegseth stated the program, which includes testosterone replacement therapy (TRT) for those diagnosed with deficiencies, would help keep personnel on the "leading edge of lethality." By Thursday, the Defense Health Agency (DHA) website had removed the memo and a related statement from spokesperson Sean Parnell.
Medical experts have raised questions regarding the scientific basis for broad screening. Derek Griffith, director of the program for research on men’s health at the University of Pennsylvania, previously told The Hill that only 2 percent of the male population typically has low testosterone, suggesting the condition may not be a widespread issue in the military. Other doctors cited by Reuters expressed concern that universal screening could lead to unnecessary or harmful treatments without clear evidence that it improves combat readiness.
Service members would notice the impact during their yearly medical exams, where they would have been required to complete questionnaires and undergo blood draws based on the now-rescinded September 2 guidance. For those eventually diagnosed with low testosterone, the program offered access to hormone treatments intended to optimize physical performance. Conversely, medical professionals warned that the implementation of such a broad mandate could lead to the over-prescription of hormones for individuals who might not otherwise require medical intervention.
The temporary withdrawal of these rules leaves the final standards for military health optimization in flux as the Pentagon works on updates. The U.S. Food and Drug Administration (FDA) is scheduled to hold a meeting of experts in mid-September 2026 to discuss the medical use of testosterone, which may provide further context for future military medical regulations. The Pentagon official stated that final clinical guidance is expected to be issued "shortly," though no specific deadline was provided.